WVE Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

6.645

Open

6.470

VWAP

6.55

Vol

3.55M

Mkt Cap

1.27B

Low

6.430

Amount

23.25M

EV/EBITDA(TTM)

--

Total Shares

192.40M

EV

700.25M

EV/OCF(TTM)

--

P/S(TTM)

16.04

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company's diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease, as well as several preclinical programs utilizing the Company's broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).

Show More

Events Timeline

(ET)

2026-05-18

16:40:00

Wave Life Sciences Updates WVE-006 Trial Data

2026-05-12 (ET)

2026-05-12

16:20:00

Major Averages Finish Mixed as Semiconductor Stocks Pull Back

2026-05-12

10:50:00

Trump Plans to Reduce Beef Import Tariffs

2026-05-11 (ET)

2026-05-11

12:30:00

Trump Approves Firing of FDA Commissioner Makary

2026-05-11

10:20:00

Trump Plans to Fire FDA Commissioner, Biotech Stocks Affected

2026-05-08 (ET)

2026-05-08

16:30:00

Dow Jones Slightly Up, Nasdaq Surges After Jobs Report

2026-05-08

13:40:00

Trump Signs Plan to Fire FDA Commissioner Makary

News

Globenewswire

05-27Globenewswire

Wave Life Sciences Under Investigation for Securities Violations

NASDAQ.COM

05-22NASDAQ.COM

Biotech Sector Regulatory Approvals and Collaborations

Newsfilter

05-19Newsfilter

AlphaDetect Partners with Wave Life Sciences to Enhance Detection Efforts

PRnewswire

05-19PRnewswire

Wave Life Sciences Sponsors AlphaDetect to Enhance Detection Efforts

stocktwits

05-18stocktwits

Wave Life Sciences Reports Positive Early Results for WVE-006 Treatment

Newsfilter

05-18Newsfilter

WVE-006 Shows Significant Potential in Treating AAT Deficiency

14 Analyst Rating

Wall Street analysts forecast WVE stock price to rise

14 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

33.00

High

50.00

Current: 0.000

Low

21.00

Averages

33.00

High

50.00

Wells Fargo

NULL

to

Overweight

maintain

$13 -> $14

AI Analysis

2026-05-20

Reason

Wells Fargo

Price Target

$13 -> $14

AI Analysis

2026-05-20

maintain

NULL

to

Overweight

Reason

Wells Fargo raised the firm's price target on Wave Life Sciences to $14 from $13 and keeps an Overweight rating on the shares. The firm notes the WVE-007 update included 600mg SAD data, which looked better than low/mid doses on M/Z-AAT and seems protective. However, the efficacy is lower than BEAM-302. Wells is moving probability of success up to 33%.

H.C. Wainwright

Buy

downgrade

$18 -> $13

2026-05-19

Reason

H.C. Wainwright

Price Target

$18 -> $13

2026-05-19

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Wave Life Sciences to $13 from $18 and keeps a Buy rating on the shares. WVE-006's readout at the American Thoracic Society Conference validated RNA editing as a modality but fell short with respect to the landscape, the analyst tells investors in a research note. The firm says Sanofi's concurrent Phase 2 data raise the commercial bar, and BEAM-302 retains a 12-18 month regulatory lead. H.C. Wainwright believes WVE-006 "delivered an underwhelming readout."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for WVE

Unlock Now

Valuation Metrics

The current forward P/E ratio for WAVE Life Sciences Ltd (WVE.O) is 0.00, compared to its 5-year average forward P/E of -5.29. For a more detailed relative valuation and DCF analysis to assess WAVE Life Sciences Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.29

Current PE

0.00

Overvalued PE

-1.85

Undervalued PE

-8.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.06

Current EV/EBITDA

-20.91

Overvalued EV/EBITDA

1.37

Undervalued EV/EBITDA

-7.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

16.66

Current PS

24.07

Overvalued PS

29.04

Undervalued PS

4.28

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Intellectia · 54 candidates

Market Cap: >= 2.00BAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Hesai Group

3.73B

Riot Platforms Inc

5.75B

Spyre Therapeutics Inc

2.48B

Immunovant Inc

5.24B

Edgewise Therapeutics Inc

2.98B

Nuvalent Inc

7.99B

Whales Holding WVE

Bluebox Asset Management Uk Ltd.

Emerald Advisers, LLC

Driehaus Capital Management LLC

Artal Group S.A.

Affinity Asset Advisors, LLC

Maverick Capital, Ltd.

Trading Trends

People Also Watch

Frequently Asked Questions

What is WAVE Life Sciences Ltd (WVE) stock price today?

The current price of WVE is 6.58 USD — it has increased 1.7

What is WAVE Life Sciences Ltd (WVE)'s business?

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company's diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease, as well as several preclinical programs utilizing the Company's broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).

What is the price predicton of WVE Stock?

Wall Street analysts forecast WVE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WVE is33.00 USD with a low forecast of 21.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is WAVE Life Sciences Ltd (WVE)'s revenue for the last quarter?

WAVE Life Sciences Ltd revenue for the last quarter amounts to 38.25M USD, increased 316.85

What is WAVE Life Sciences Ltd (WVE)'s earnings per share (EPS) for the last quarter?

WAVE Life Sciences Ltd. EPS for the last quarter amounts to -0.13 USD, decreased -55.17

How many employees does WAVE Life Sciences Ltd (WVE). have?

WAVE Life Sciences Ltd (WVE) has 317 emplpoyees as of May 31 2026.

What is WAVE Life Sciences Ltd (WVE) market cap?

Today WVE has the market capitalization of 1.27B USD.